|2.||Neoplasm Metastasis (Metastasis)
|4.||Breast Neoplasms (Breast Cancer)
|1.||Zhang, Wei: 683 articles (01/2016 - 01/2002)|
|2.||Li, Yan: 550 articles (02/2016 - 03/2002)|
|3.||Wang, Wei: 523 articles (12/2015 - 01/2002)|
|4.||Li, Wei: 464 articles (02/2016 - 01/2002)|
|5.||Li, Li: 424 articles (01/2016 - 01/2002)|
|6.||Zhang, Li: 382 articles (01/2016 - 06/2002)|
|7.||Wang, Yan: 367 articles (01/2016 - 01/2002)|
|8.||Li, Jing: 363 articles (01/2016 - 03/2002)|
|9.||Wang, Jing: 350 articles (01/2016 - 07/2002)|
|10.||Wang, Li: 326 articles (01/2016 - 05/2002)|
|1.||Cisplatin (Platino)FDA LinkGeneric
02/01/2015 - "Cisplatin is highly effective in the treatment of cervical cancer. "
12/01/2014 - "Cisplatin is a commonly-used chemotherapeutic agent that is highly-effective against a variety of pediatric cancers. "
04/01/2013 - "Cisplatin has been considered as the most effective agent for metastatic cervical cancer. "
01/01/2013 - "Cisplatin is one of the most important chemotherapeutic agents useful in the treatment of a variety of solid tumors; however, it has several side effects such as nephrotoxicity. "
08/01/2011 - "Although cisplatin attacks various tumors with remarkable efficacy, its clinical usage has been limited by its side effects, particularly nephrotoxicity. "
02/01/1987 - "In our own studies two types of approaches were also effective with the highly metastatic mouse tumor line ESb which carries a weak tumor associated antigen. "
01/01/2015 - "However, high-avidity TCRs are not always available, particularly among self/tumor antigen-specific T cells, most of which are eliminated by central and peripheral deletion mechanisms. "
01/01/2014 - "In this way, through the use of adjuvants, immune responses can be highly customizable and functionally tailored for optimal efficacy against pathogen specific (i.e., infectious agent) or non-pathogen (i.e., cancer) antigens. "
05/01/2013 - "Antigen-specific CD8+ T cells (pmel-1) or CD4+ T cells (tyrosinase-related protein-1) expressing DNRII dramatically improved tumor treatment efficacy. "
06/01/2007 - "The Ab/SA conjugate yielding the best tumor uptake and tumor-to-normal organ ratios of radioactivity varied depending on the target antigen expression on the cell line used, with 1F5/SA and Lym-1/SA yielding the most promising results overall. "
|3.||DNA (Deoxyribonucleic Acid)IBA
09/01/2010 - "Consistent with the biological phenotype, epigenomic studies revealed that TRAMP; Dnmt1 hypomorphic mice show dramatically reduced CpG island and promoter DNA hypermethylation in late-stage primary tumors compared to control mice. "
09/01/2010 - "Improved detection methods have led to increased knowledge on cell-free DNA, and recent studies showed that most cancer patients have increased levels of cell-free DNA. "
04/01/2015 - "DNA damaging agents (ionizing radiation and chemotherapeutics) are considered as most effective in cancer treatment. "
01/01/2015 - "Small-molecule inhibitors of PARP appear most effective when used to treat tumors with underlying defects in DNA repair, or when combined with DNA-damaging agents. "
11/03/2014 - "They were found to be significantly active as DNA cleaving agents in vitro and showed highly improved cancer regression in MCF-7 and MD-MB231 cancer cells compared to small molecule DNA cleaver. "
|4.||Doxorubicin (Adriamycin)FDA LinkGeneric
01/14/2014 - "Taken together, these findings demonstrate that SQ-Dox nanoassemblies make tumor cells more sensitive to doxorubicin and reduce the cardiac toxicity, thus providing a remarkable improvement in the drug's therapeutic index. "
04/01/2013 - "Doxorubicin (DOX) is one of the most effective anti-cancer drugs, but its therapeutic efficacy is greatly hampered by its non-specific delivery to the target tissue and the resultant cumulative cardiotoxicity and nephrotoxicity. "
03/15/2009 - "Our results showed the remarkable capability of 2C5-targeted Doxil to specifically deliver its cargo into various tumors, significantly increasing the efficacy of therapy."
01/01/2009 - "Our results clearly show the remarkable capability of 2C5-targeted Doxil to specifically deliver its cargo into various tumor manifestations (solid and metastatic) significantly increasing the efficacy of therapy."
03/15/2006 - "Doxorubicin (DOX) is a highly effective treatment for several forms of cancer. "
|5.||Paclitaxel (Taxol)FDA LinkGeneric
01/01/2013 - "It has proven resistant in clinical trials to chemotherapeutic agents such as paclitaxel that are highly effective in vitro, presumably because of impaired drug delivery across the tumor's blood-brain barrier (BBB). "
01/01/2014 - "Compared to treatment with paclitaxel alone, treatment with combination of paclitaxel and ETA achieved significant reduction in volume and weight of HeLa tumors (p<0.05), and remarkable inhibition to the growth of KB-3-1 tumors (p<10⁻⁶). "
01/01/2013 - "All the target compounds showed improved anti-proliferative activity against a panel of human cancer cell lines and the most effective compound 12j was more potent than positive control Taxol in K562 and Bel-7402 cells with IC(50) values of 0.39 μM and 1.39 μM, respectively. "
07/14/2011 - "The microtubule-targeting antineoplastic agent, paclitaxel, is highly efficacious against a wide spectrum of human cancers. "
01/01/2011 - "Paclitaxel is highly effective in the treatment of many cancers in humans, but cannot be routinely used in dogs as currently formulated due to the exquisite sensitivity of this species to surfactant-solubilizing agents. "
|6.||Biological Markers (Surrogate Marker)IBA
01/01/1996 - "Short-term clinical trials then determine optimal dosing and characterize the efficacy of the best agents against intermediate biomarkers of cancer. "
01/01/2015 - "In medical practice, biomarkers can be helpful in finding out one's potential cancer risk, confirming whether or not one is already affected with a particular type of cancer, to which drug will the cancer respond best and in what doses should it be administered, the effectiveness of the treatment and whether the cancer will recur. "
01/01/2015 - "Current clinically approved cancer biomarkers are most effective when applied to patients with widespread cancer. "
01/01/2014 - "Antiangiogenic strategies directed towards tumor stroma are becoming gold standard in NSCLC treatment and researchers have been searching for biomarkers to identify patients for whom therapy with antiangiogenic inhibitors may be most beneficial and the importance of these as prognostic factors in NSCLC. "
08/01/2013 - "Since response to treatments is conditioned by individual factors, the use of new biological markers as novel predictive factors for both tumor and normal tissues could help clinicians to choose the best treatment schedule for each patient individually. "
|7.||Fluorouracil (Carac)FDA LinkGeneric
04/01/2004 - "Combined treatment with 5-FU and AxE1AdB-UPRT dramatically reduced the disseminated tumor burden without causing toxicity in normal tissues. "
06/30/2000 - "Effective treatment of certain cancers with 5-fluorouracil (5-FU) and irradiation is well established; however, the most effective combination of these agents remains controversial. "
09/01/1999 - "DPD activity is highly variable in cancer populations, and this variation may influence the antitumor efficacy of 5-fluorouracil. "
09/01/1987 - "To date, HDFA + 5-FU is one of the most effective treatments for large bowel cancer."
01/01/1996 - "Several studies suggest that protracted continuous infusion constitutes an important way to optimize the dose and the efficacy of 5-fluorouracil (5-FU) in metastatic cancer. "
07/01/2005 - "Local interleukin 2 therapy is most effective against cancer when injected intratumourally."
11/20/1997 - "However, in a short-term therapy model, continued IL-2 expression was most effective against 3-day established tumors. "
03/23/1994 - "Because IL-2 does not have a direct effect on cancer cells but rather mediates its antitumor activity by altering host immune reactions, these data represent the best available evidence that immunologic therapy for cancer can be effective in selected patients."
04/07/1993 - "Our results suggest that induction of anti-tumor immune response by local IL-2 production is most effective when the helper cytokine is secreted by the tumor cell. "
01/01/1993 - "On the other hand, several groups have shown that application of intratumoral low doses of IL-2 can be highly effective against cancer and without toxic side-effects. "
05/01/2001 - "Initial clinical trials with the HPV types which are most prevalent in cervical cancer exhibited promising results, yet next generation vaccines are already under development."
01/01/2015 - "A combined HPV-16/18 prevalence of 69.9% in ICC specimens suggests that current vaccines will be highly protective against cervical cancer in Zambia."
01/01/2014 - "Current protective virus-like particle and capsid-based vaccines are highly protective against vaccine-matched HPV types, and continued improvements in second-generation vaccines will lead to broader protection and cross-protection against the cancer-associated types. "
02/01/2012 - "While the development of anti-HPV prophylactic vaccines represents one of the most remarkable triumphs of modern medicine, there is much more to be done in terms of advancing safe and effective treatments for cervical and head-and-neck cancers. "
01/01/2012 - "Vaccines giving best protection against solid tumor growth corresponded to the archaeosome adjuvant composition that gave highest immune activity in immunized mice."
12/03/2014 - "NMOFs thus represent a new class of highly potent PDT agents and hold great promise in treating resistant cancers in the clinic. "
01/01/2014 - "As most cancers are being treated with combined therapies, PDT is being integrated into rationally designed regimens that exploit molecular responses to PDT for improved efficacy. "
12/01/2013 - "In vivo PDT experiment based magnetic tumor targeting using IONC-PEG-Ce6 is finally carried out, achieving high therapeutic efficacy with dramatically delayed tumor growth after just a single injection and the MF-enhanced photodynamic treatment. "
04/01/2013 - "The efficacy of ALA-PDT is highly dependent on the photosensitizer (PS) concentration present in the tumor. "
06/01/2010 - "PDT was highly selective, safe, significantly improved good quality survival, and delayed tumor relapse (p < 0.001). "
|1.||Drug Therapy (Chemotherapy)
05/01/2015 - "The neoadjuvant metronomic chemotherapy regimen evaluated in this trial was highly effective in achieving a tumor response, especially in the HER2+ cohort. "
02/01/2015 - "Number needed to treat is highly variable among the different trials according to patient's characteristics, tumor biology and the efficacy of chemotherapy administered. "
01/01/2015 - "Radiation Therapy Oncology Group (RTOG) 1205 will establish the role of re-irradiation for recurrent GBM, however our study suggests that CyberKnife with chemotherapy can be safely delivered, and is most effective in patients with smaller frontal lobe tumors, good performance status, or long interval from diagnosis."
09/07/2014 - "The advent of cytoreduction (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has dramatically improved survival outcomes with wide median survival estimates between 2.5 to 9 years; these studies however remain largely heterogeneous, with differing study populations, tumor biology, and specific treatment regimens. "
01/01/2011 - "More recent trials have suggested that for advanced NSCLC patients with EGFR mutant tumors, initial therapy with a TKI instead of chemotherapy may be the best choice of treatment. "
01/01/2015 - "To get cancer under control requires us to perform complex clinical studies that integrate drugs, companion diagnostics, new or improved surgical procedures and new radiotherapy approaches as well as, most importantly, to integrate all available information. "
01/01/2015 - "This study demonstrated that for HNMM patients surgery is recommended if indicated, and surgery combined with postoperative radiotherapy is also recommended for dramatically improved local control of the tumor bed. "
07/01/2013 - "Although many studies have demonstrated improved outcomes with the use of radiotherapy for small- to medium-sized VSs, surgery is still the most commonly used treatment modality for these tumors. "
04/01/2012 - "Randomized multicenter controlled trials evaluating efficacy of conservation surgery and definitive radiotherapy, and correctly interpreting functional outcome for each of the treatment procedures examined are necessary to obtain sufficient evidence to influence the decision in the choice of the most effective treatment for early pyriform sinus cancer."
12/01/2015 - "LNEC may be best treated depending on its histologic differentiation, with surgery being beneficial for early grade tumors while radiotherapy is inconclusive in its benefit for late-stage disease."
|3.||Heterologous Transplantation (Xenotransplantation)
01/01/2014 - "Furthermore, the most powerful compound identified in this study, the 3-[(R)-3-pyrrolidinyl]oxime derivative (3-R-POD), was highly effective in various tumor cell lines in vitro, and exhibited significant tumor growth inhibition in prostate and lung xenografts in vivo. "
12/01/2012 - "Herein, we propose a hypothesis based on this novel conception that if transplanted as an organ, tumor implantation in nude mice would conserve most approximated biological traits with improved success rate, which make personalized tumor xenograft model practical for pre-clinical trials as substitutes for each patient. "
12/16/2015 - "One selected ADC was shown to induce tumor regression in a xenograft model at a single dose of 3 mg/kg, demonstrating that PPTase-mediated conjugation is suitable for the production of highly efficacious and homogeneous ADCs. "
11/10/2015 - "Importantly, As2O3 treatment dramatically reduced GSC population in the intracranial GBM xenografts and increased the survival of mice bearing the tumors. "
11/01/2015 - "In vivo efficacy of LY2523355 is highly dose/schedule-dependent, achieving complete remission in a number of xenograft tumor models, including patient-derived xenograft (PDX) tumor models. "
04/01/2013 - "In this study, we explored the therapeutic efficacy of an irradiated AdVEGFR2-infected cell vaccine-based immunotherapy in the weakly immunogenic and highly metastatic 4T1 murine mammary cancer model. "
01/01/2013 - "Notably, recent clinical studies have revealed that PD-1-directed immunotherapy is highly effective in cancer patients, demonstrating that PD-1 is a promising therapeutic target in humans. "
01/01/2013 - "Although many reports demonstrate the efficacy of cancer immunotherapies in numerous preclinical studies, most experiments have been performed in young animals. "
09/01/2005 - "This study shows that DC maturation with cytokine cocktails different from those most commonly used could be beneficial for immunotherapy trials in cancer patients."
01/01/2004 - "DC-based immunotherapy has shown early promise in clinical cancer trials, and efforts are being made to determine the optimal method of delivery of cells to achieve the best outcome. "
08/01/2013 - "Most therapeutics have shown to be more effective when used in combination with standard therapies, resulting in concomitant telomere shortening and tumor mass shrinkage, as well as preventing tumor relapse and resistance to single agent therapy."
11/01/2011 - "The identification of G36 as a GPER antagonist with improved ER counterselectivity represents a significant step towards the development of new highly selective therapeutics for cancer and other diseases."
06/01/2011 - "This targeted strategy holds promise in paving the way for the introduction of highly effective nanoscopic vehicles for cancer therapeutics while overcoming drug resistance."
01/01/2010 - "Intrinsic and acquired cellular resistance factors limit the efficacy of most targeted cancer therapeutics. "
08/01/2008 - "The past decade has witnessed the unveiling of a powerful new generation of genetically engineered mouse (GEM) models of human cancer, which are proving to be highly effective for elucidating cancer mechanisms and interrogating novel experimental therapeutics. "